STAR THERAPEUTICS ANNOUNCES $200 MILLION PRIVATE FINANCING TO ADVANCE PIPELINE OF BEST-IN-DISEASE THERAPIES Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and continued pipeline expansion...
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class...
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted...
Recent Comments